

a.) Amendments to Specification

Please amend Table 2 at page 47 to read as follows:

Table 2

HS	MAFNDCFSLNYPGNPCPGDLIEVFRPGYQHWALYLG DG YVINIAPVDGIP-ASFTSAKSV	
	. * * * * * . * * * * . * * * * * . * * * * . * * * * .	
HR	MRAPIPEPKPGDLIEIFRPFYRHWAIYVGDGYVVHLAPPSEVAGAGAASVMSA	
HS	FSSKALVKMQLLKDVGN DTYRINN KYDETY PPLPVEEIIKRSEFVIGQEVAYNLLVNNC	
	. . . * * . * * . * * . * * . * * . * * . * * . * * . * * . * * . * * . * * .	
HR	LTDKAI VKKELLYDVAGSDKYQVNNKHDDKYSPLPCTKIIQRAEELVGQEVLYKLTSENC	
HS	EHFVTLRLRYGEGVSEQANRAISTVEFVTAAGVGFSLG-LFPKGQRAKYY	(SEQ ID NO:1)
	* * * * . * * * * . * . * . . * * . * . * . * . * . * . * .	
HR	EHFVNELRYGVARS DQVRDVIIAASVAGMGLAAMSLIGVMFSRNKRQKQ	(SEQ ID NO:29)

Please amend Table 3 at page 48 to read as follows:

Table 3

HS	MASPHQEPKPGDLIEIFRLGYEHWALYIG DG YVIHLAPPSEYPGAGSSSVFSVLSNSAEV	
	* . * . * * * * * * * * * * . * * * . * * * * * * * * * * . * * * . * * * . * * . * * .	
HR	MRAPIPEPKPGDLIEIFRPFYRHWAIYVGDGYVVHLAPPSEVAGAGAASVMSALTDKAI	
HS	KRERLEDVVGCCYRVNNSLDHEYQPRPVEVI ISSAKEMVGQKMKYSIVSRNCEHFVTQL	
	* . * * * * . * . * * . * . * * * . * * . * . * . * * * . * . . . * * * * * . * .	
HR	KKELLYDVAGSDKYQVNNKHDDKYSPLPCTKIIQRAEELVGQEVLYKLTSENCEHFVNEL	
HS	RYGKSRCKQVEKAKVEGVAT-ALGILVVAGCSFAIRRYQKKATA	(SEQ ID NO:2)
	* * * . * . * * * * . * . . * . * . . * * .	
HR	RYGVARS DQVRDVIIAASVAGMGLAAMSLIGVMFSRNKRQKQ	(SEQ ID NO:29)

Please amend Table 4 at page 53 to read as follows:

Table 4

HS	MVAKQRIRMANEKHSKNITQRGNVAKTSRNASPEEKASVGPWLLALFIFVVCESAIFQIIQ
	*..***. .**.. ***...*****. . .*. * ...***. **.*****.*.***.
CE	MAPKQRMTLANKQFSKNVNNRGNVAKSLK-PAEDKYPAAPWLIGLFVFVVCESAIFQIIQ
HS	SIRMG (SEQ ID NO:6)
	..**
CE	YVKMG (SEQ ID NO:30)

Please add an Abstract of Disclosure as new page 61 as follows:

ABSTRACT OF DISCLOSURE

The present invention relates to human proteins having transmembrane domains and cDNAs coding for these proteins as well as eucaryotic cells expressing said cDNAs. The proteins of the present invention are useful for proliferation of neural cells and for regeneration of nerve and brain tissues, i.e., for the treatment of central and peripheral nervous system disease and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue.